5-Star Stocks Poised to Pop: IDEXX Labs
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, IDEXX Laboratories (NAS: IDXX) has earned a coveted five-star ranking.
With that in mind, let's take a closer look at IDEXX's business and see what CAPS investors are saying about the stock right now.
IDEXX facts
Headquarters (founded) | Westbrook, Maine (1983) |
Market Cap | $5.1 billion |
Industry | Health care equipment |
Trailing-12-Month Revenue | $1.3 billion |
Management | Chairman/CEO Jonathan Ayers |
Return on Equity (average, past 3 years) | 27.5% |
Cash/Debt | $201.8 million / $247.0 million |
Competitors | Abaxis |
Sources: S&P Capital IQ and Motley Fool CAPS.
On CAPS, 95% of the 236 members who have rated IDEXX believe the stock will outperform the S&P 500 going forward.
Just last month, one of those Fools, TMFJLo, succinctly summed up the bull case for our community:
A bit expensive, but IDEXX is a technology healthcare leader not only for animals, but also for humans. Cloud computing that connects diagnostics labs to clinics = exceptional idea. No competitors to speak of and aggressive recruiting incentives (free software). 5 straight quarters of beating expectations doesn't hurt, either.
If you want market-topping returns, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future. Of course, despite its five-star rating, IDEXX may not be your top choice.
We've found another stock we are incredibly excited about -- excited enough to dub it "The Motley Fool's Top Stock for 2012." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.
Want to see how well (or not so well) the stocks in this series are performing? Follow theTrackPoisedToCAPS account.
The article 5-Star Stocks Poised to Pop: IDEXX Labs originally appeared on Fool.com.
Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of VCA Antech. Motley Fool newsletter services have recommended writing covered calls on VCA Antech. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
